Fate Therapeutics (FATE) Income towards Parent Company (2012 - 2026)

Fate Therapeutics has reported Income towards Parent Company for 15 years, with the latest figure at -$31.1 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 17.95% year-over-year to -$31.1 million; the trailing twelve-month figure through Mar 2026 stood at -$129.8 million (up 29.44% YoY), and the FY2025 full-year result was -$136.7 million, up 29.19% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$31.1 million, up from -$32.5 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$24.9 million in Q1 2023, with the low at -$84.6 million in Q3 2022.
• Historically, Income towards Parent Company has averaged -$49.2 million across 5 years, with a median of -$46.6 million in 2023.
• Annual changes were most pronounced in 2023 — Income towards Parent Company jumped 66.38% — and 2024, when it slumped 88.44%.
• Fate Therapeutics' Income towards Parent Company stood at -$61.5 million in 2022, then gained by 29.05% to -$43.7 million in 2023, then tumbled by 32.55% to -$57.9 million in 2024, then jumped by 43.84% to -$32.5 million in 2025, then climbed by 4.21% to -$31.1 million in 2026.
• The last three Income towards Parent Company figures came in at -$31.1 million (Q1 2026), -$32.5 million (Q4 2025), and -$32.2 million (Q3 2025), per Business Quant data.